All In Biotech

Drug Trial Radar · NCT05979311

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

A Phase 3b, Multi-center, Randomized, Parallel-group, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Oral Dolutegravir/Lamivudine Once-daily as a First-line Regimen Compared to Oral Bictegravir/Emtricitabine/Tenofovir Alafenamide Once Daily for Virologic Suppression and Maintenance in Antiretroviral Therapy Naive Adults Living With HIV

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 463 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

463

Actual

Start

Feb 21, 2024

Primary completion

Apr 15, 2026

Study completion Mar 26, 2027

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Aug 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare safety, efficacy, participant reported outcomes and implementation outcomes of a fixed dose combination (FDC) of a two-drug regimen dolutegravir (DTG) plus lamivudine (3TC) and a three-drug regimen FDC of bictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF) in HIV-1 infected adult participants who have not previously received antiretroviral therapy.

Conditions

  • HIV
  • HIV Infections

Interventions

  • DolutegravirDrug

    Dolutegravir will be administered once daily.

  • LamivudineDrug

    Lamivudine will be administered once daily.

  • BictegravirDrug

    Bictegravir will be administered once daily.

  • EmtricitabineDrug

    Emtricitabine will be administered once daily.

  • Tenofovir alafenamideDrug

    Tenofovir alafenamide will be administered once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with plasma HIV- Ribonucleic acid (RNA) less than (<)50 copies per milliliter (c/mL) as per snapshot algorithm at Week 48Time frame: Week 48

Locations

64 sites in 17 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina

  • GSK Investigational Site

    Córdoba, Argentina

  • GSK Investigational Site

    Antwerp, Belgium

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Brussels, Brussels Capital, Belgium

  • GSK Investigational Site

    Hvidovre, Denmark

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Montpellier, France

  • GSK Investigational Site

    Nice, France

  • GSK Investigational Site

    Nîmes, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Cologne, Germany

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    München, Germany

  • GSK Investigational Site

    Frankfurt am Main, Hesse, Germany

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Thessaloniki, Greece

  • GSK Investigational Site

    Dublin, Ireland

  • GSK Investigational Site

    Dublin, Ireland

  • GSK Investigational Site

    Haifa, Israel

  • GSK Investigational Site

    Ramat Gan, Israel

  • GSK Investigational Site

    Rehovot, Israel

  • GSK Investigational Site

    Tel Aviv, Israel

  • GSK Investigational Site

    Bari, Italy

  • GSK Investigational Site

    Bergamo, Italy

  • GSK Investigational Site

    Padova, Italy

  • GSK Investigational Site

    Pavia, Italy

  • GSK Investigational Site

    Sassari, Italy

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Mérida, Mexico

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.